Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

High-affinity HLA-DP4/WT1 cognate T cell receptor screening using a novel reporter system

EF 2020-21

Résumé
Adoptive cell therapy is an immunotherapeutic strategy that engineers the natural human immune system to target cancers. T cell, a type of immune cell, recognizes peptide fragments (antigens) presented in complex with a molecule called major histocompatibility complex (MHC) on host cells, through surface molecules T cell receptors (TCR). In adoptive T cell therapy, tumour-responsive TCR are incorporated in natural T cells to redirect their specificity toward specific tumours. This strategy has elicited promising results targeting various diseases and provides perspectives for future tumour therapies. However, one obstacle underway is that most identified cancer-targeting T cells exhibit insufficient affinity for effective recognition of tumour antigens. One approach to tackle this challenge is to artificially enhance the affinity of the TCR while minimizing any toxicities. Here, we aim to engineer TCR responsive for Wilm's Tumour 1 (WT1), a tumour antigen expressed on various leukemia, such as acute myelogenous leukemia (AML), and solid tumours. Through manipulating the TCR gene sequence, TCR molecular structures will ultimately be altered and can elicit optimal targeting effects. In addition, unlike the current T cell therapeutic approach that primarily utilizes TCR targeting MHC-I restricted antigens, we will investigate TCR targeting MHC-II, which have been hypothesized to elicit a longer-lasting and broader anti-tumour response. This project will bring more insight into the future trajectory of adoptive T cell therapy and potentially contribute to therapeutics for patients who cannot benefit from the current immunotherapeutic strategies.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449660
Name
Zheng Yi Fei
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
High-affinity HLA-DP4/WT1 cognate T cell receptor screening using a novel reporter system
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive T Cell Therapy; Affinity; Cancer; Cd4 T Cell; Hla-Dp4; Mhc-Ii; T Cell Receptor; T Cell Reporter System; Wilm’S Tumour 1
Abstract
Adoptive cell therapy is an immunotherapeutic strategy that engineers the natural human immune system to target cancers. T cell, a type of immune cell, recognizes peptide fragments (antigens) presented in complex with a molecule called major histocompatibility complex (MHC) on host cells, through surface molecules T cell receptors (TCR). In adoptive T cell therapy, tumour-responsive TCR are incorporated in natural T cells to redirect their specificity toward specific tumours. This strategy has elicited promising results targeting various diseases and provides perspectives for future tumour therapies. However, one obstacle underway is that most identified cancer-targeting T cells exhibit insufficient affinity for effective recognition of tumour antigens. One approach to tackle this challenge is to artificially enhance the affinity of the TCR while minimizing any toxicities. Here, we aim to engineer TCR responsive for Wilm's Tumour 1 (WT1), a tumour antigen expressed on various leukemia, such as acute myelogenous leukemia (AML), and solid tumours. Through manipulating the TCR gene sequence, TCR molecular structures will ultimately be altered and can elicit optimal targeting effects. In addition, unlike the current T cell therapeutic approach that primarily utilizes TCR targeting MHC-I restricted antigens, we will investigate TCR targeting MHC-II, which have been hypothesized to elicit a longer-lasting and broader anti-tumour response. This project will bring more insight into the future trajectory of adoptive T cell therapy and potentially contribute to therapeutics for patients who cannot benefit from the current immunotherapeutic strategies.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zheng, Yi Fei
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~